Health Trials

Cord Blood Transplantation in Children and Young Adults With Blood Cancer

ConditionsAcute Myelogenous LeukemiaAcute Lymphoblastic LeukemiaMyelodysplastic SyndromesNon-hodgkin LymphomaHodgkin LymphomaLeukemiaLymphomaGraft-versus-host Disease
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
AgeUp to 26
SponsorMemorial Sloan Kettering Cancer Center

About this trial

The purpose of this study is to find out whether Cord Blood Transplantation/CBT as the first or second transplant is an effective treatment for children and young adults with blood cancer.

Eligibility criteria

Qualifiers

Known prior diagnosis of myelodysplasia (MDS)

High risk cytogenetics (e.g., those associated with MDS, abnormalities of 5, 7, 8, complex karyotype) and/or high-risk molecular abnormalities (e.g., TP53)

Requirement for 2 or more inductions to achieve CR1

Therapy-related AML (t-AML) or therapy-related myeloid neoplasm (t-MN) (including after therapy for other malignancy, and/or gene therapy or cell therapy)

Disqualifiers

Chloroma >2 cm.

Active and uncontrolled infection (bacterial/fungal/viral) at time of transplant.

HIV infection.

Seropositivity for HTLV-1.

Trial design

Treatments tested in this trial

  • Cord Blood Units
  • Total Body Irradiation
  • Cyclophosphamide
  • Fludarabine
  • Clofarabine
  • Busulfan
  • Thiotepa
  • Tacrolimus
  • Mycophenolate Mofetil
  • Cyclosporine

Treatment groups

71 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Memorial Sloan Kettering Cancer Center

Lead sponsor

Source ClinicalTrials.gov